Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AVI-6002 · 1 trial · 1 indication
The frequency and severity of adverse events will be monitored through 28 days post administration.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | - |
| AVI-6002 | EXPERIMENTAL | Phosphorodiamidate morpholino antisense oligomer with positive charges on selected subunits (PMOplus™) |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Normal saline |
| AVI-6002 | DRUG | Single intravenous administration |
Inclusion Criteria: * Male or female and between the ages of 18 and 50 years in good general health * Volunteers must be willing to use barrier methods of contraception or be of non-childbearing potential * Volunteers must be willing to undergo a urine screen for drugs of abuse Exclusion Criteria:...
AVI-6002 is an investigational small molecule being developed for the prevention of Ebola Hemorrhagic Fever. It is designed as a post-exposure prophylaxis treatment for Ebola virus infection. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
AVI-6002 is being developed by Sarepta Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol SRPT. The company is conducting clinical trials to evaluate the safety of this investigational drug for Ebola Hemorrhagic Fever.
AVI-6002 is in Phase 1 clinical development. A Phase 1 clinical trial has been completed to evaluate the safety of the drug. It is an investigational product and has not received FDA approval. The drug is being studied as a post-exposure prophylaxis treatment for Ebola virus.
AVI-6002 has been studied in one clinical trial, identified as NCT01353027. This was a Phase 1, randomized, double-blind, placebo-controlled study titled 'Safety Study of Single Administration Post-Exposure Prophylaxis Treatment for Ebola Virus'. The trial was completed in the United States and enrolled 30 healthy volunteers aged 18 years and older.
AVI-6002 is a distinct investigational drug developed by Sarepta Therapeutics. It is a small molecule designed for post-exposure prophylaxis of Ebola virus infection. No alternative names for AVI-6002 have been disclosed, and it is not the same as other approved or investigational Ebola treatments.